Baidu
map

Diabetes Care:用慢病保健模式可改善糖尿病患者心血管风险

2014-02-19 高晓方 译 医学论坛网

瑞士一项研究表明,在对2型糖尿病患者的治疗中,应用慢性疾病保健模式(CCM)并纳入执业护理可改善心血管疾病风险,但未能改善血糖控制;研究者进一步指出这种模式即使在小型初级保健的实践中也可执行。论文于2月10日在线发表于《糖尿病护理》(Diabetes Care)杂志。此项研究共纳入326例年龄大于18岁的2型糖尿病患者,并随机分入干预组和对照组。受试者在过去一年中至少出现过一次糖化血红蛋白(HbA

瑞士一项研究表明,在对2型糖尿病患者的治疗中,应用慢性疾病保健模式(CCM)并纳入执业护理可改善心血管疾病风险,但未能改善血糖控制;研究者进一步指出这种模式即使在小型初级保健的实践中也可执行。论文于2月10日在线发表于《糖尿病护理》(Diabetes Care)杂志。 【原文下载】

此项研究共纳入326例年龄大于18岁的2型糖尿病患者,并随机分入干预组和对照组。受试者在过去一年中至少出现过一次糖化血红蛋白(HbA1c)≥7.0%。干预包括在2型糖尿病患者治疗中应用CCM原理以及纳入执业护理。主要转归为HbA1c水平,次要转归为血压、低密度脂蛋白胆固醇(LDL—C)、CCM依从性和生活质量。

结果显示,1年后两组患者的HbA1c水平均显著降低,并且两组之间无显著差异(P=0.708)。与对照组相比,干预组患者的收缩压、舒张压、LD—C和CCM依从性均显著改善。两组患者的生活质量评分无显著差异。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636817, encodeId=fb15163681e17, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 21 23:07:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901182, encodeId=3b56190118259, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 18 05:07:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082342, encodeId=d47220823420a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Jan 01 09:07:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759407, encodeId=dc8f1e594070a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Sep 05 10:07:00 CST 2014, time=2014-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473769, encodeId=a3fa14e376962, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Feb 21 05:07:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636817, encodeId=fb15163681e17, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 21 23:07:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901182, encodeId=3b56190118259, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 18 05:07:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082342, encodeId=d47220823420a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Jan 01 09:07:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759407, encodeId=dc8f1e594070a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Sep 05 10:07:00 CST 2014, time=2014-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473769, encodeId=a3fa14e376962, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Feb 21 05:07:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636817, encodeId=fb15163681e17, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 21 23:07:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901182, encodeId=3b56190118259, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 18 05:07:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082342, encodeId=d47220823420a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Jan 01 09:07:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759407, encodeId=dc8f1e594070a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Sep 05 10:07:00 CST 2014, time=2014-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473769, encodeId=a3fa14e376962, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Feb 21 05:07:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636817, encodeId=fb15163681e17, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 21 23:07:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901182, encodeId=3b56190118259, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 18 05:07:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082342, encodeId=d47220823420a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Jan 01 09:07:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759407, encodeId=dc8f1e594070a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Sep 05 10:07:00 CST 2014, time=2014-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473769, encodeId=a3fa14e376962, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Feb 21 05:07:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]
    2014-09-05 智智灵药
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636817, encodeId=fb15163681e17, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Wed Jan 21 23:07:00 CST 2015, time=2015-01-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1901182, encodeId=3b56190118259, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Tue Mar 18 05:07:00 CST 2014, time=2014-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2082342, encodeId=d47220823420a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Jan 01 09:07:00 CST 2015, time=2015-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759407, encodeId=dc8f1e594070a, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Fri Sep 05 10:07:00 CST 2014, time=2014-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473769, encodeId=a3fa14e376962, content=<a href='/topic/show?id=935fe6718e3' target=_blank style='color:#2F92EE;'>#糖尿病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76718, encryptionId=935fe6718e3, topicName=糖尿病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a38f7243741, createdName=xue8604, createdTime=Fri Feb 21 05:07:00 CST 2014, time=2014-02-21, status=1, ipAttribution=)]

相关资讯

Medical Care:网络管理有助提高糖尿病患者他汀类药物治疗依从性

旧金山综合医院内科临床部和加利福尼亚大学的UrmimalaSarkar博士及其研究团队研究发现,糖尿病患者仅使用网络管理系统复诊,不仅提高了糖尿病患者他汀类药物治疗的依从性,而且降低LDL-C的水平。该研究结果发表在2013年12月26日的Medical Care杂志。Sarkar博士团队认为,利用网络预约门诊、查看化验结果、开具处方及与网站的服务人员进行交流,这种看病模式在医疗保健机构中会逐渐增

BMJ:ACEI为糖尿病患者**降压药

我国台湾学者简国龙、杜裕康等新近发表的一项荟萃分析显示,血管紧张素转换酶抑制剂(ACEI)在成年糖尿病患者中是首选的抗高血压治疗药物。该研究发表于10月24日的《英国医学杂志》(BMJ)。   研究人员通过对PubMed、Medline、Scopus、Cochrane等数据的检索,分析了63项随机试验。这些试验在近37,000位患有糖尿病的成年人中评价了11种不同的降压治疗方案。研究终点

JAMA:糖尿病患者使用电子病历与其看急诊、住院次数减少有关

据9月11日发表在《美国医学会杂志》上的一则研究披露,糖尿病患者使用综合医疗救治体系提供的一种门诊病人电子病历(EHR)与其看急诊及住院次数的适度减少有关,但与其去诊所就诊的次数变化无关。【原文下载】 经济与临床卫生信息技术健康(HITECH)法案授权在10年的时间里拨款高达270亿美元用以促进有意义的EHRs使用,并从2015年开始会对不使用EHR的做法加以处罚。在这些重大的激励措施下

糖尿病患者半数有耳聋、耳鸣

许多糖尿病患者年纪不大,却开始出现听力下降的情况,不仅听不清别人讲话,还时不时伴有耳鸣,严重者甚至耳聋,其实这都是糖尿病的不良反应,糖尿病可引起听力提早老化,流行病学显示,约半数患者有耳聋、耳鸣。 糖代谢异常 糖代谢异常可以造成内耳功能改变,因为糖和糖代谢提供了内耳主要的能量来源,血浆中持续高血糖可以导致淋巴中葡萄糖水平和内淋巴的直流电位改变,据此有学者认为由于葡萄糖代谢影响了内耳主动转运系统

Diabetes Care:社区干预降糖尿病患者的HbA1c不显著

美国一项研究表明,社区卫生工作者(CHW)干预并未显著降低糖尿病患者的糖化血红蛋白(HbA1c)水平,并且增加干预精确度可能实现更好的血糖控制。论文于2月4日在线发表于《糖尿病护理》(Diabetes Care)。【原文下载】 此项研究共纳入360例近期HbA1c≥8%、年龄介于35~70岁的西班牙裔受试者,并随机给予12个月的CHW干预(181例)或常规治疗(179例)。主要转归为12个月时

EAPCIP2013:CAD患者每日2次给药可缓解阿司匹林抵抗

巴黎——一项纳入92例患者的单中心交叉试验表明,在糖尿病合并冠状动脉疾病(CAD)患者中,阿司匹林每日2次给药方案阻断血小板聚集的效果明显优于总剂量相同的每日1次给药方案。 在欧洲经皮心血管介入学会(EAPCI)2013年会上,法国巴黎Lariboisière医院心脏科的Jean-Guillaume Dillinger医生报告称,与未患糖尿病的患者相比,糖尿病患者往往对心血管事

Baidu
map
Baidu
map
Baidu
map